Seeking out great stocks to buy is essential, but many would say it’s even more important to know which stocks to steer clear of. A losing stock can eat away at your precious long-term returns. So, figuring out which stocks to trim or get rid of is essential for proper portfolio maintenance.
Even the best gardens need pruning, and our team has spotted a few stocks that seem like prime candidates for selling or avoiding. Continue reading to find out which three stocks our team is staying away from this week.
TRUE MARKET INSIDERS:
Warning: Move Your Money ASAP
The clock just started on the biggest stock market event in twenty years. And the next couple months could determine who will become extremely wealthy in 2022 – and who won’t. [Full Story…]
Communications software company Everbridge (EVBG) made it to our list after the release of dismal 2022 guidance and the announcement of a poorly timed change in management. The company announced the resignation of CEO David Meredith and gave no explanation for him unexpectedly giving up his seat. In the interim, Everbridge’s CFO and VP Patrick Brickly and CRO Vernon Irvin will act as Co-Ceo’s until a permanent replacement is found.
BofA analyst Brad Sills downgraded Everbridge to Underperform from Neutral with a price target of $100, down from $175. The analyst cites the company’s announcement of the transition of its CEO. “The CFO and CRO of Everbridge are capable executives, but the CEO transition creates an overhang and also puts into question the overall future direction of the business,” Sills tells investors in a research note.
Everbridge also offered an initial look into revenue guidance for 2022. The company sees 20%-23% growth, well below Wall Street expectations. With growth decelerating 36% in 2021 to 23% in 2022, there are a lot of unanswered questions that management has yet to address.
JPMorgan analyst Sterling Auty also downgraded EVBG to Neutral from Overweight with a price target of $127, down from $200. The analyst believes the new 2022 growth guidance is likely to further solidify growth deceleration concerns, “especially with the possibility of disruption from the leadership change.”
Jeff Bezos Just Poured $10 Billion Into This…
Not many people know this story… But in 1998, Bezos invested $250,000 of his own money in Google, when the company was just getting started out of a garage in California. When Google went public in 2004, that $250,000 investment translated into 3.3 million shares of Google stock. Nobody knows if Bezos has sold any shares. If he hasn’t, today they’re worth more than $5.6 billion.Jeff Bezos is betting big on a new trend. This time he’s planning to invest $10 billion of his own money in this exciting new trend. That’s 40,000 times more money than what he invested in Google. That’s how big he thinks this could be. [Full Story…]
The announcement of a poorly timed transition in CEOs followed by dismal FY21 preliminary figures put biomedical instrument developer Berkeley Lights (BLI) at the top of our list this week.
It was revealed that Berkeley Lights is initiating a search for a new CEO as current CEO Eric Hobbs, Ph.D., will transition from his role as chief executive officer and member of the board of directors to the president of the Antibody Therapeutics business line. William Blair Analyst Brian Weinstein called the transition “unconventional” when he downgraded BLI to Market Perform from Outperform on Thursday. The announcement came in tandem with a peek into a less productive 2021 that Wall Street expects.
We’ll get a look at BLI’s full financial results for the fourth quarter and full-year 2021 in late February, but results based on management’s initial analysis are pointing to a steep revenue miss. The pros are looking for $90.85M in revenue for the full year. By Berkeley Lights preliminary calculations, the company expects just $84M-$84.5M in 2021 revenue. If that’s not bad enough, the company adjusted 2022 guidance below the consensus expectations. Stifel analyst Daniel Arias put it best – BLI “seems bound to be dead money for a while.” We’ll keep our distance pending further developments.
New in Biotech:
The Guardian: “New pill could spell the end of all disease.”
This pill is set to completely change the lives of millions of Americans.
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams. [Full Story…]
School bus maker Blue Bird Corp. (BLBD) could be the beneficiary of increased infrastructure spending in the years to come. However, ongoing supply chain disruptions and increasing cost of materials have taken a toll and are expected to hold back 2022 production. BLBD makes our list of stocks to avoid after a dismal earnings call where the company reported misses on the top and bottom lines for the fourth quarter and lowered 2022 guidance.
The company cited supply chain snags as the cause for its Q4 production miss. Over 2,000 school bus deliveries were pushed back into fiscal 2022. Things could get worse before they get better for Bluebird. Sure, the company’s backlog is at a record high, but the 4,200 units currently in backlog are mostly at fixed price commitments that predate an 11% price increase for inflation, and there has been talk of at least one more price increase in 2022.
Roth Capital analyst Craig Irwin recently lowered the firm’s price target to $13 from $21 and kept a Neutral rating for BLBD. The analyst cited the “ugly Q4 results” and uncertainty around the expected infrastructure funding, due in part to heavy funding support for EV busses.
The good news for Blue Bird is that school bus demand has largely recovered to pre-pandemic levels, and order strength has returned. Until supply chain and material cost issues are in the rearview, we’ll stay away from this one.
The U.S. Economy is headed for trouble…
Why are stocks absolutely soaring right now…? Yet at the same time millions of Americans are out of work… Commercial bankruptcies are piling up… Delinquent credit card debt is skyrocketing… Not to mention, we are smack in the middle of a pandemic that has all but forced our economy to a grinding halt… Something’s just not adding up. Friend, if you are confused by all of this… You are not alone… [Full Story]